GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
The company has received the GMP Certification after successful closure of the inspection
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Lidocaine and Prilocaine cream had annual sales of US $22.05 million in the United States (IQVIA MAT October 2024)
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Subscribe To Our Newsletter & Stay Updated
